

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70728 A1

(51) International Patent Classification⁷: C07D 401/04,
491/04, 401/14, 495/04, 471/04, A61K 31/506, A61P
25/28

(21) International Application Number: PCT/EP01/03639

(22) International Filing Date: 22 March 2001 (22.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00400801.7 23 March 2000 (23.03.2000) EP
00400802.5 23 March 2000 (23.03.2000) EP
00400803.3 23 March 2000 (23.03.2000) EP

(71) Applicants (for all designated States except US):
SANOFI-SYNTHELABO [FR/FR]; 174, avenue de France, F-75013 Paris (FR). MITSUBISHI-TOKYO PHARMACEUTICALS, INC. [JP/JP]; 2-6, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8405 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ALMARIO

GARCIA, Antonio [ES/FR]; 26, avenue Roger Salengro, F-92290 Chatenay Malabry (FR). ANDO, Ryoichi [JP/JP]; c/o Mitsubishi-Tokyo Pharmaceuticals, Inc., Yokohama Research Center, 1000, Kamoshida-cho, Aoba-Ku, Yokohama-shi, Kanagawa 227-0033 (JP). FROST, Jonathan, Reid [GB/FR]; 12, rue du Parc, F-91320 Wissous (FR). LI, Adrien, Tak [FR/FR]; 14, rue Pierre Bonnard, F-92260 Fontenay aux Roses (FR). SHODA, Aya [JP/JP]; c/o Mitsubishi-Tokyo Pharmaceuticals, Inc., Yokohama Research Center, 1000, Kamoshida-cho, Aoba-ku, Yokohama-shi, Kanagawa 227-0033 (JP).





(74) Agent: KUGEL, Dominique; Sanofi-Synthelabo, 174 Avenue de France, F-75013 Paris (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: 2-[NITROGEN-HETEROCYCLIC]PYRIMIDONE DERIVATIVES



(57) Abstract: A pyrimidone derivative represented by formula (I) or a salt thereof wherein: R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C₁₋₄ alkyl group, C₁₋₄ alkoxy group or a halogen atom; (a) represents a [nitrogen-heterocyclic ring] of formula (X), (Y) or (Z). And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease.



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guide-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

SPECIFICATION

2-[NITROGEN-HETEROCYCLIC]PYRIMIDONE DERIVATIVES

5 Technical Field

The present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal activity of GSK3 β .

10 Background Art

GSK3 β (glycogen synthase kinase 3 β) is a proline directed serine, threonine kinase that plays an important role in the control of metabolism, differentiation and survival. It was initially identified as an enzyme able to 15 phosphorylate and hence inhibit glycogen synthase. It was later recognized that GSK3 β was identical to tau protein kinase 1 (TPK1), an enzyme that phosphorylates tau protein in epitopes that are also found to be hyperphosphorylated in Alzheimer's disease and in several taupathies.

Interestingly, protein kinase B (AKT) phosphorylation of GSK3 β results in a loss of 20 its kinase activity, and it has been hypothesized that this inhibition may mediate some of the effects of neurotrophic factors. Moreover, phosphorylation by GSK3 β of β -catenin, a protein involved in cell survival, results in its degradation by an ubiquitination dependent proteasome pathway.

Thus, it appears that inhibition of GSK3 β activity may result in neurotrophic activity.

25 Indeed there is evidence that lithium, an uncompetitive inhibitor of GSK3 β , enhances neuritogenesis in some models and also increases neuronal survival, through the induction of survival factors such as Bcl-2 and the inhibition of the expression of proapoptotic factors such as P53 and Bax.

Recent studies have demonstrated that β -amyloid increases the GSK3 β activity 30 and tau protein phosphorylation. Moreover, this hyperphosphorylation as well as the neurotoxic effects of β -amyloid are blocked by lithium chloride and by a GSK3 β antisense mRNA. These observations strongly suggest that GSK3 β may be the link between the two major pathological processes in Alzheimer's disease: abnormal APP (Amyloid Precursor Protein) processing and tau protein 35 hyperphosphorylation.


Although tau hyperphosphorylation results in a destabilization of the neuronal cytoskeleton, the pathological consequences of abnormal GSK3 β activity are, most likely, not only due to a pathological phosphorylation of tau protein because,

as mentioned above, an excessive activity of this kinase may affect survival through the modulation of the expression of apoptotic and antiapoptotic factors. Moreover, it has been shown that β -amyloid-induced increase in GSK3 β activity results in the phosphorylation and, hence the inhibition of pyruvate dehydrogenase, a pivotal enzyme in energy production and acetylcholine synthesis.

5 Altogether these experimental observations indicate that GSK3 β may find application in the treatment of the neuropathological consequences and the cognitive and attention deficits associated with Alzheimer's disease, as well as other acute and chronic neurodegenerative diseases. These include, in a non-limiting manner, Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others
10 traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma.

In addition GSK3 β may find application in the treatment of other diseases such as:

20 Non-insulin dependent diabetes (such as diabetes type II) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors.
25 PCT application WO 98/24782 discloses compounds represented by the following formula (A):



(A)

30 wherein R represents a 2,6-dichlorobenzyl group, a 2-(2-chlorophenyl)ethylamino group, a 3-phenylpropylamino group, or a 1-methyl-3-phenylpropylamino group.

The compounds represented by formula (A) are characterized by a 4-fluorophenyl group at the 5-position of the pyrimidine ring. The main pharmacological activity disclosed for the compounds represented by formula (A) is an anti-inflammatory effect, whereas the compounds of the present invention represented by formula (I)

5 herein below are useful as GSK3 β inhibitors or as medicaments for the therapeutic treatment of neurodegenerative diseases, and therefore, their pharmacological activities are totally different.


Disclosure of the Invention

An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3 β activity, more particularly of neurodegenerative diseases. More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables prevention and/or treatment of the neurodegenerative diseases such as Alzheimer's disease.

Thus, the inventors of the present invention have identified compounds possessing inhibitory activity against GSK3 β . As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases.

15

The present invention thus provides pyrimidone derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof:




(I)

5 wherein:

R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C₁₋₄ alkyl group, C₁₋₄ alkoxy group or a halogen atom;

10

 represents a [nitrogen-heterocyclic ring] of formula X, Y or Z



15 Wherein

R2 represents

- * a C₆₋₁₀ aryl group,
- * a heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of

20 5-10, or






- * a C₁₋₆ alkyl group substituted by 1 to 3 substituents selected from

- a hydroxyl group,
- a C₃₋₆ cycloalkyl group
- a C₆₋₁₀ aryl group and

25 - a heterocyclic ring as defined above; and

n represents 1 or 2;

Z being selected from the group consisting of :



wherein R3 represents a hydrogen atom or a C₁₋₆ alkyl group;

5

the C₆₋₁₀ aryl groups and heterocyclic ring being optionally substituted by 1 to 3 substituents selected from a C₁₋₆ alkyl group, halogen atom, a C₁₋₂ perhalogenated alkyl group, a C₁₋₃ halogenated alkyl group, a hydroxyl group, a C₁₋₆ alkoxy group, methylenedioxy group, a nitro, a cyano or a phenyl group.

10

According to another aspect of the present invention, there is provided a medicament comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivatives represented by formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates

15

thereof. As preferred embodiments of the medicament, there are provided the aforementioned medicament which is used for preventive and/or therapeutic treatment of diseases caused by abnormal GSK3β activity, and the aforementioned medicament which is used for preventive and/or therapeutic treatment of neurodegenerative diseases and in addition other diseases such as:

20

Non-insulin dependent diabetes (such as diabetes type II) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors.

25

As further preferred embodiments of the present invention, there are provided the aforementioned medicament wherein the diseases are neurodegenerative diseases and are selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and

30

other dementia including vascular dementia; acute stroke and others traumatic

injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma, and the aforementioned medicament in the form of pharmaceutical composition containing the above substance as an active ingredient together with one or more 5 pharmaceutical additives.

The present invention further provides an inhibitor of GSK3 β activity comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the salts thereof, and the solvates 10 thereof and the hydrates thereof.

According to further aspects of the present invention, there are provided a method for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal GSK3 β activity, which comprises the step of administering to 15 a patient a preventively and/or therapeutically effective amount of a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof; and a use of a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the physiologically acceptable salts 20 thereof, and the solvates thereof and the hydrates thereof for the manufacture of the aforementioned medicament.

As used herein the C₁₋₆ alkyl group represents a straight or branched alkyl group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, n- 25 propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group, n-hexyl group, isohexyl group, and the like;

The C₃₋₆ cycloalkyl group represents a cyclic alkyl group of 3 to 6 carbon atoms, for example, cyclopropyl, 2-methyl cyclopropyl, 2-ethyl cyclopropyl 30 cyclobutyl, cyclopentyl, cyclohexyl, and the like;

The C₁₋₆ alkoxy group represents an alkyloxy group having 1 to 6 carbon atoms for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, isopentyloxy group, neopentyloxy group, 1,1-dimethylpropyloxy 35 group;

The halogen atom represents a fluorine, chlorine, bromine or iodine atom;

The C₁₋₂ perhalogenated alkyl group represents an alkyl group wherein all the hydrogen have been substituted by a halogen atom, for example a CF₃ or

C₂F₅:

The C₁₋₃ halogenated alkyl group represents an alkyl group wherein at least one hydrogen has not been substituted by a halogen atom;

5 The C₆₋₁₀ aryl group represents a phenyl group, 1-naphthyl group, 2-naphthyl group and tetrahydronaphthyl group;

The heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10 represents a furan ring, dihydrofuran ring, tetrahydrofuran ring, pyran ring, dihydropyran ring, tetrahydropyran ring, benzofuran ring, furopyridine ring, 10 isobenzofuran ring, chromene ring, chroman ring, isochroman ring, thiophene ring, benzothiophene ring, thienopyridine ring, pyrrole ring, pyrrolidine ring, pyrrolidone ring, imidazole ring, imidazoline ring, imidazolidine ring, imidazopyridine ring, pyrazole ring, pyrazoline ring, pyrazolidine ring, triazole ring, tetrazole ring, pyridine ring, pyridine oxide ring, piperidine ring, pyrazine ring, piperazine ring, 15 pyrimidine ring, pyridazine ring, indolizine ring, indole ring, indoline ring, isoindole ring, isoindoline ring, indazole ring, benzimidazole ring, purine ring, quinolizine ring, quinoline ring, isoquinoline ring, phthalazine ring, naphthyridine ring, quinoxaline ring, quinazoline ring, cinnoline ring, pteridine ring, oxazole ring, oxazolidine ring, isoxazole ring, isoxazolidine ring, thiazole ring, benzothiazole 20 ring, thiazylidine ring, isothiazole ring, isothiazolidine ring, dioxane ring, dithian ring, morpholine ring, thiomorpholine ring, phthalimide ring and the like.

The compounds represented by the aforementioned formula (I) may form a salt. Examples of the salt include, when an acidic group exists, salts of alkali 25 metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, N,N-bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N-methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, 30 δ-hydroxylysine, and arginine. The base-addition salts of acidic compounds are prepared by standard procedures well known in the art.

When a basic group exists, examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; 35 salts with organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, propionic acid, tartaric acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic

acid, and salicylic acid; or salts with acidic amino acids such as aspartic acid, and glutamic acid.

The acid-addition salts of the basic compounds are prepared by standard procedures well known in the art which include, but are not limited thereto, dissolving the free base in an aqueous alcohol solution containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and an acid in an organic solvent, in which case the salt separates directly, or is precipitated with a second organic solvent, or can be obtained by concentration of the solution. The acids which can be used to prepare the acid-addition salts include preferably those which produce, when combined with the free base, pharmaceutically-acceptable salts, that is, salts whose anions are relatively innocuous to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not compromised by side effects ascribable to the anions. Although medicinally acceptable salts of the basic compounds are preferred, all acid-addition salts are within the scope of the present invention.

In addition to the pyrimidone derivatives represented by the aforementioned formula (I) and salts thereof, their solvates and hydrates also fall within the scope of the present invention. The pyrimidone derivatives represented by the aforementioned formula (I) may have one or more asymmetric carbon atoms. As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the pyrimidone derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. Any stereoisomers in pure form, any mixtures of stereoisomers, racemates and the like fall within the scope of the present invention.

Furthermore, as the pyrimidone derivatives represented by the aforementioned formula (I), a 3H-4-one compound, a 4-hydroxy compound, and a 1H-4-one compound may exist as tautomers. The existence of such tautomers is readily apparent to those skilled in the art, and these tautomers fall within the scope of the present invention.

Examples of preferred compounds of the present invention are shown in tables hereinafter. However, the scope of the present invention is not limited by these compounds.

Preferred compounds of the present invention represented by formula (I) include also:

(1) Compounds wherein R1 represents a 3- or 4-pyridyl group and more preferably 5 4-pyridyl group, which may be substituted by a C₁₋₂ alkyl group, C₁₋₂ alkoxy group or a halogen atom;

(2) When the [nitrogen-heterocyclic ring] is of formula X, compounds wherein R2 represents 10 * a C_{6,10} aryl group,
* a heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10, or
* a C₁₋₆ alkyl group substituted by one C_{6,10} aryl group.

15 More preferred compounds of the present invention represented by formula (I) include also:

(1) Compounds wherein R1 represents an unsubstituted 4-pyridyl group;

20 (2) When the [nitrogen-heterocyclic ring] is of formula X :
a) Compounds wherein R2 represents a phenyl or substituted phenyl ring, a naphthyl or substituted naphthyl ring or a tetrahydronaphthyl or a substituted tetrahydronaphthyl ring, or
b) Compounds wherein R2 represents a heterocyclic ring selected from 25 fuopyridine ring, thienopyridine ring, imidazopyridine ring, pyridine ring, indole ring, indoline ring, indazole ring, benzimidazole ring, quinoline ring, isoquinoline ring and pyrimidine ring; and more preferably furo[3,2-c]pyridine ring, thieno[3,2-c]pyridine ring, imidazo[4,5-c]pyridine ring, imidazo[1,2-a]pyridine ring, indole ring, indoline ring, indazole ring, benzimidazole ring, quinoline ring, 30 isoquinoline ring, pyridine ring and pyrimidine ring, and / or
c) Compounds wherein n is 1;

(3) When the [nitrogen-heterocyclic ring] is of formula Y, compounds wherein R2 represents a heterocyclic ring selected from a furan ring, imidazole ring, and 35 indoline ring;

(4) When the [nitrogen-heterocyclic ring] is of formula Z, compounds wherein the [nitrogen-heterocyclic ring] is selected from :

2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole,

1,2,3,4-tetrahydroisoquinoline,

5 4,5,6,7-tetrahydrothieno[2,3-c]pyridine, and
1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine;

(5) Compounds wherein R1 is as defined under (1) and the [nitrogen-heterocyclic ring] and eventually R2 are as defined under (2), (3) or (4).

10

Particularly preferred compounds of the present invention represented by formula (I) include:

2-[4-(2,5-dimethylphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(7-ethoxynaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

15 2-[4-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(4-methoxyphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(4-chlorophenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(pyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

20 2-[4-(7-fluoronaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(7-propoxynaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(7-(2-methylethoxy)naphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(pyrimidin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

25 2-[4-(2-phenylphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(phenylmethyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(phenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-[3,4-(methylenedioxy)phenyl]piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(3-trifluoromethylpyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

30 2-[4-(5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(quinolin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(imidazo[1,2-a]pyridin-5-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(1H-indazol-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(5-methoxy-1H-indol-3-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

35 2-[4-(imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(1H-indazol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-(4-methoxy-1H-benzimidazol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-

4(1H)-one,

2-[4-(1H-indol-5-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperazin-1-yl]-6-pyridin-4-
ylpyrimidin-4(1H)-one,
2-[4-(3-phenylpropyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
5 2-[4-(isoquinolin-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(furo[3,2-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(4-cyanopyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(thieno[3,2-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(2,3-dihydro-1H-indol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one.
10 2-[4-(1-methyl-1H-indol-3-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-[phenylmethyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-[(4-methoxyphenyl)methyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(2-phenylethyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
15 2-[4-[hydroxy(furan-2-yl)methyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(2-cyclohexylpropyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(1H-imidazol-4-yl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(phenylmethyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(1H-indol-3-yl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
20 2-[4-(indolin-5-yl)piperidinyl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
6-pyridin-4-yl-2-[2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-yl]pyrimidin-4(1H)-one,
6-pyridin-4-yl-2-[1,2,3,4-tetrahydroisoquinolin-2-yl]pyrimidin-4(1H)-one,
6-pyridin-4-yl-2-[6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl]pyrimidin-4(1H)-
one,
25 6-pyridin-4-yl-2-[4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl]pyrimidin-4(1H)-one
and
6-pyridin-4-yl-2-[1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridin-2-yl]pyrimidin-4(1H)-
one.


As a further object, the present invention concerns also methods for preparing the pyrimidone compounds represented by the aforementioned formula (I).

These compounds can be prepared, for example, according to methods explained
5 below.

When the [nitrogen-heterocyclic ring] is of formula X, compounds of formula (I) may prepared according to preparation method 1.

10 1. Preparation Method 1

scheme 1



(In the above scheme, R represents an alkyl group, which may be substituted, and definitions of R₁, R₂ and n are the same as those already described above for compound of formula (I)).

The 3-ketoester represented by the above formula (II) is allowed to react with the compound represented by formula (III) or a salt thereof to obtain the compound of the aforementioned formula(I) in the presence of a base such as lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, lithium methoxide, sodium methoxide, potassium methoxide, lithium ethoxide, sodium ethoxide, potassium ethoxide, 1,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine, diisopropyl-ethylamine, dimethylbenzylamine, dimethylaniline, diethylaniline and the like.

25 Examples of a solvent suitable for the reaction include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbon solvents such as benzene, toluene, xylene; halogenated solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar

solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide and the like. Generally, a single solvent or a mixture of two or more solvents may be used depending on the base used, and the reaction may be carried out for 1 hour to 14 days at a suitable temperature ranging from 0° to 250°C under nitrogen or argon atmosphere or in ordinary air.

Compounds of formula (II) and formula (III) are commercially available or may be synthesized according to known methods of one skilled in the art.

10


For example compounds of formula (II), wherein R1 represent a 4-pyridyl group optionally substituted by a C₁₋₄ alkyl group, C₁₋₄ alkoxy group or a halogen atom, can be prepared by reacting a nicotinic acid optionally substituted by a C₁₋₄ alkyl group, C₁₋₄ alkoxy group or an halogen, with a malonic acid monoester. The 15 reaction can be carried out using methods well known to one skilled in the art, such as for example in presence of a coupling agent such as 1,1'-carbonylbis-1H-imidazole in a solvent such as a tetrahydrofuran at a temperature ranging from 20 to 70°C.

20 2. Preparation method 2

Alternatively pyrimidine compounds represented by the aforementioned formula (I) may be prepared according to scheme 2.

25

Scheme 2



(In the above scheme the definition of R1 is the same as already described above).


30

The 2-methylthio derivative represented by the above formula (IV), wherein R2 is as defined for compound of formula (I), is allowed to react with an amine of formula (V) to obtain the compound of the aforementioned formula (I).
 5 The reaction may be carried out in a solvent such as, for example, an alcoholic solvent such as n-pentanol or isoamyl alcohol at a suitable temperature ranging from 100 to 180 °C under ordinary air.

Compound of formula (IV) may be prepared according to the method defined in scheme 3.

10

Scheme 3



(In the above scheme the definition of R and R1 are the same as those already described above).

15 According to this method, the 3-ketoester of formula (II) is allowed to react with a 2-methyl-2-thiopseudourea sulfate. The reaction may be carried out in solvent such as water or an alcohol, such as ethanol, propanol and butanol, at a suitable temperature ranging from 25-100°C under ordinary air.

20 Compounds of formula (V) are commercially available or may be synthesized according to well-known methods of one skilled in the art.

In addition when applicable, compound of formula (I) can be derivatised into other compound of formula (I), using well known methods in the art, for
 25 example when the C_{6,10} aryl groups or the heterocyclic ring is substituted by a hydroxyl group, the hydroxyl group can be alkylated to give a C₁₋₆ alkoxy group.

In the above reactions, protection or deprotection of a functional group may sometimes be necessary. A suitable protecting group can be chosen depending on the type of a functional group, and a method described in the
 30 literature may be applied. Examples of protecting groups, of protection and deprotection methods are given for example in *Protective groups in Organic*

Synthesis Greene et al., 2nd Ed. (John Wiley & Sons, Inc., New York).

The compounds of the present invention have inhibitory activity against GSK3 β .

Accordingly, the compounds of the present invention are useful as an active

5 ingredient for the preparation of a medicament, which enables preventive and/or therapeutic treatment of a disease caused by abnormal GSK3 β activity and more particularly of neurodegenerative diseases such as Alzheimer's disease. In addition, the compounds of the present invention are also useful as an active ingredient for the preparation of a medicament for preventive and/or therapeutic

10 treatment of neurodegenerative diseases such as Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma;

15 peripheral neuropathies; retinopathies and glaucoma; and other diseases such as non-insulin dependent diabetes (such as diabetes type II) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors.

20

The present invention further relates to a method for treating neurodegenerative diseases caused by abnormal activity of GSK3 β and of the aforementioned diseases which comprises administering to a mammalian organism in need thereof an effective amount of a compound of the formula (I).

25

As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof. The 30 substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more of pharmaceutical additives. As the active ingredient of the medicament of the present invention, two or more of the 35 aforementioned substances may be used in combination. The above pharmaceutical composition may be supplemented with an active ingredient of another medicament for the treatment of the above mentioned diseases. A type of the pharmaceutical composition is not particularly limited, and the composition

may be provided as any formulation for oral or parenteral administration. For example, the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions,

5 solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. Injections or drip infusions may be prepared as powdery preparations such as in the form of
10 10 lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline. Sustained-release preparations such as those coated with a polymer may be directly administered intracerebrally.

15 Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content ratios of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art. Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical
20 20 additives. Generally, the pharmaceutical additives may be incorporated in a ratio ranging from 1% by weight to 90% by weight based on the weight of an active ingredient.

Examples of excipients used for the preparation of solid pharmaceutical compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin,
25 25 kaolin, calcium carbonate and the like. For the preparation of liquid compositions for oral administration, a conventional inert diluent such as water or a vegetable oil may be used. The liquid composition may contain, in addition to the inert diluent, auxiliaries such as moistening agents, suspension aids, sweeteners, aromatics, colorants, and preservatives. The liquid composition may be filled in capsules
30 30 made of an absorbable material such as gelatin. Examples of solvents or suspension mediums used for the preparation of compositions for parenteral administration, e.g. injections, suppositories, include water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, lecithin and the like. Examples of base materials used for suppositories include, for example, cacao butter,
35 35 emulsified cacao butter, lauric lipid, witepsol.

Dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen

depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. Generally, a daily dose for oral administration to an adult may be 0.01 to 1,000 mg (the weight of an active ingredient), and the dose may be
5 administered once a day or several times a day as divided portions, or once in several days. When the medicament is used as an injection, administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.

10 Chemical Examples

The present invention will be explained more specifically with reference to the following general examples, however, the scope of the present invention is not limited to these examples.

15 Example 1 : Preparation of 2-[4-(R₂ substituent)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one.

1.1. Preparation of Ethyl 3-(4-pyridyl)-3-oxopropionate

20 Isonicotinic acid (35.56 g, 289 mmol) was added to a solution of 1,1'-carbonylbis-1H-imidazole (46.98 g, 290 mmol) in tetrahydrofuran (700ml), and the resulting solution was stirred for 1.5 hr at 50°C. After cooling to room temperature, malonic acid monoester potassium salt (51.7 g, 304 mmol) and magnesium chloride (34.33 g, 361 mmol) were added, and the mixture was refluxed for 1 hr and then heated
25 at 50°C for 6 hr. The solvent was removed under reduced pressure and the residue was quenched by the addition of dilute acetic acid. The organic layer was extracted with ethyl acetate (3 times) and the combined extracts were washed with dilute aqueous sodium bicarbonate and brine, and were concentrated under reduced pressure. The residue was purified by silica gel column chromatography
30 (eluent ; hexane/ethyl acetate = 2/1 to 1/1) and recrystallization from hexane – ethyl acetate gave 41.52 g (74%) of the title compound.

1.2. Preparation of 2-[4-(R₂ substituent)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one.

35 Ethyl 3-(4-pyridyl)-3-oxopropionate (0.60g ; 3.1mmol), 1-amidino-4-(R₁ substituent)piperazine hydrochloride (3.4 mmol) and potassium carbonate (1.15g ; 8.3mmol) were added to 5 ml of ethanol, and the mixture was heated under reflux

at 75° for 20 hours. Acetic acid was added to the reaction mixture , and the solvent was removed by distillation. The residue was treated with water and then with acetic acid , and the resulting solid was separated by filtration, washed with water and ethyl acetate, and dried to obtain the desired compound.

5

2. Example 2 : Preparation of 2-[heteroaminocyclic]-6-pyridin-4-yl pyrimidin-4(1H)-one

2.1. 2-(Methylthio)-6-pyridinyl-4-ylpyrimidin-4(1H)-one

10

To a solution of 5.76 g (20.7 mmol) of 2-methyl-2-thiopseudoiourea sulfate in 48 ml of water was added 4.85 g (86.52 mmol) of potassium hydroxide. The mixture was agitated and 8.0 g (41.4 mmol) of ethyl 3-(4-pyridyl)-3-oxopropionate was added and stirring was maintained for 48 hours.

15

The precipitate was recovered by filtration and was washed with water and then ether. The product was dried at 90°C in vacuo to give 6.26 g, 69% of white solid.
Mp : 328-330°C.


2.2 2-[nitrogen-heterocyclic ring]-6-pyridin-4-ylpyrimidin-4(1H)-one

20











A solution of 1 equivalent of 2-(methylthio)-6-pyridinyl-4-ylpyrimidin-4(1H)-one and 3 to 5 equivalents of a [nitrogen-heterocyclic ring] of formula (V) were suspended in amyl alcohol (0.1 - 0.2 M) and was heated at 150°C during 72 hours.The cooled solution was concentrated and purified by chromatography on silica gel.











25

A list of chemical structures and physical data for compounds of the aforementioned formula (I) illustrating the present invention is given in the following tables.

Table 1

No.	R2	m.p.(°C)	[M+H] ⁺
1		-	362
2		-	428
3		-	418
4		-	364
5		-	368
6		262-263	335
7		-	402
8		-	442

9		-	442
10		-	336
11		-	410
12		257-259	348
13		281-283	334
14		-	392
15		-	403
16		-	403
17		-	385
18		291.8-292.2	374

19		320.9 - 321.5	374
20		-	403
21		286.2-286.5	375
22		273.3 - 273.8	374
23		249.3 - 249.6	404
24		234.8-235.1	373
25		-	448
26		183.5 - 183.8	376
27		237.7 - 238.0	385
28		-	375







29		-	360
30		273.1-273.4	391
31		209.5-209.9	375
32		-	387

Table 2

No.	R2	m.p.(°C)	[M+H] ⁺
1		-	333
2		-	377
3		-	361
4		-	353
5		-	381
6		226-228 (*)	-
7		228-230 (**)	347
8		245.9-246.1	372
9		-	374

All compounds are bases, except (*) = maleate and (**) = oxalate

Table 3

No.	Structure	m.p.(°C)	$[M+H]^+$
1		-	311
2		-	344
3		-	305
4		240.1-240.5	365
5		-	345

Test Example: Inhibitory activity of the medicament of the present invention against GSK3 β :

Two different protocols can be used.

5

In a first protocol : 7.5 μ M of prephosphorylated GS1 peptide and 10 μ M ATP (containing 300,000 cpm of 33P-ATP) were incubated in 25 mM Tris-HCl, pH 7.5, 0.6 mM DTT, 6 mM MgCl₂, 0.6 mM EGTA, 0.05 mg/ml BSA buffer for 1 hour at room temperature in the presence of GSK3 β (total reaction volume : 100

10 microliters).

In a second protocol : 4.1 μ M of prephosphorylated GS1 peptide and 42 μ M ATP (containing 260,000 cpm 33P-ATP) were incubated in 80 mM Mes-NaOH, pH 6.5, 1 mM Mg acetate, 0.5 mM EGTA, 5 mM 2-mercaptoethanol, 0.02% Tween 20, 15 10% glycerol buffer for 2 hours at room temperature in the presence of GSK3 β . Inhibitors were solubilised in DMSO (final solvent concentration in the reaction medium, 1%).

The reaction was stopped with 100 microliters of a solution made of 25 g 20 polyphosphoric acid (85% P₂O₅), 126 ml 85% H₃PO₄, H₂O to 500 ml and then diluted to 1:100 before use. An aliquot of the reaction mixture was then transferred to Whatman P81 cation exchange filters and rinsed with the solution described above. Incorporated 33P radioactivity was determined by liquid scintillation spectrometry.

25 The phosphorylated GS-1 peptide had the following sequence :

NH₂-YRRAAVPPSPSLSRHSSPHQS(P)EDEE-COOH.

The GSK3 β inhibitory activity of the compounds of the present invention are expressed in IC₅₀, and as an illustration the range of IC₅₀'s for the compound in the 30 table 1 is between 0.1 to 10 micromolar concentrations.

Formulation Example**(1) Tablets**

The ingredients below were mixed by an ordinary method and
5 compressed by using a conventional apparatus.

Compound of Example 1	30 mg
Crystalline cellulose	60 mg
Corn starch	100 mg
Lactose	200 mg
10 Magnesium stearate	4 mg

(2) Soft capsules

The ingredients below were mixed by an ordinary method and filled in soft
capsules.

15 Compound of Example 1	30 mg
Olive oil	300 mg
Lecithin	20 mg

(1) Parenteral preparations

20 The ingredients below were mixed by an ordinary method to prepare
injections contained in a 1 ml ampoule.

Compound of Example 1	3 mg
Sodium chloride	4 mg
25 Distilled water for injection	1 ml


Industrial Applicability

30 The compounds of the present invention have GSK3 β inhibitory activity
and are useful as an active ingredient of a medicament for preventive and/or
therapeutic treatment of diseases caused by abnormal activity of GSK3 β and more
particularly of neurodegenerative diseases.

What is claimed is:

1. A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof:

5




wherein:

R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C₁₋₄ alkyl group, C₁₋₄ alkoxy group or a halogen atom;

10

N represents a [nitrogen-heterocyclic ring] of formula X, Y or Z



Wherein

R2 represents

* a C₆₋₁₀ aryl group,

20 * a heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10, or

* a C₁₋₆ alkyl group substituted by 1 to 3 substituents selected from

- a hydroxyl group,

- a C₃₋₆ cycloalkyl group


- a C₆₋₁₀ aryl group and

- a heterocyclic ring as defined above;

25

n represents 1 or 2;

Z being selected from the group consisting of :



wherein R3 represents a hydrogen atom or a C₁₋₆ alkyl group;

5

the C_{6,10} aryl groups and heterocyclic ring being optionally substituted by 1 to 3 substituents selected from a C₁₋₆ alkyl group, halogen atom, a C₁₋₂ perhalogenated alkyl group, a C₁₋₃ halogenated alkyl group, a hydroxyl group, a C₁₋₆ alkoxy group, methylenedioxy group, a nitro, a cyano or a phenyl group.

10

2. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1, wherein R1 represents an unsubstituted 4-pyridyl group.

15

3. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein the [nitrogen-heterocyclic ring] is of formula X and R2 represents

20

- * a C_{6,10} aryl group,
- * a heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10, or
- * a C₁₋₆ alkyl group substituted by one C_{6,10} aryl group.

4. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein the [nitrogen-heterocyclic ring] is of formula X and

a) R2 represents a phenyl or substituted phenyl ring, a naphthyl or substituted naphthyl ring or a tetrahydronaphthyl or a substituted tetrahydronaphthyl ring,
5 or

b) R2 represents a heterocyclic ring selected from fuopyridine ring, thienopyridine ring, imidazopyridine ring, pyridine ring, indole ring, indoline ring, indazole ring, benzimidazole ring, quinoline ring, isoquinoline ring and pyrimidine ring; and more preferably furo[3,2-c]pyridine ring, thieno[3,2-c]pyridine ring, imidazo[4,5-c]pyridine ring, imidazo[1,2-a]pyridine ring, indole ring, indoline ring, indazole ring, benzimidazole ring, quinoline ring, isoquinoline ring, pyridine ring and pyrimidine ring, and / or
10

c) n is 1.

15

5. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein the [nitrogen-heterocyclic ring] is of formula Y and R2 represents a heterocyclic ring selected from a furan ring, imidazole ring, and indoline ring.

20

6. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein the [nitrogen-heterocyclic ring] is of formula Z and is selected from :

2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole,

25

1,2,3,4-tetrahydroisoquinoline,

4,5,6,7-tetrahydrothieno[2,3-c]pyridine, and

1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine.

7. A pyrimidone derivative which is selected from the group consisting of:

30 2-[4-(2,5-dimethylphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(7-ethoxynaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]-6-pyridin-4-
ylpyrimidin-4(1H)-one,
2-[4-(4-methoxyphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
35 2-[4-(4-chlorophenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(pyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(7-fluoronaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(7-propoxynaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,

2-[4-[7-(2-methylethoxy)naphth-1-yl]piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(pyrimidin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(2-phenylphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
5 2-[4-(phenylmethyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(phenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-[3,4-(methylenedioxy)phenyl]piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(3-trifluoromethylpyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
10 2-[4-(quinolin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(imidazo[1,2-a]pyridin-5-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(1H-indazol-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(5-methoxy-1H-indol-3-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
15 2-[4-(1H-indazol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(4-methoxy-1H-benzimidazol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-
4(1H)-one,
2-[4-(1H-indol-5-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperazin-1-yl]-6-pyridin-4-
20 ylpymidin-4(1H)-one,
2-[4-(3-phenylpropyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(isoquinolin-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(furo[3,2-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(4-cyanopyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
25 2-[4-(thieno[3,2-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(2,3-dihydro-1H-indol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(1-methyl-1H-indol-3-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-[(4-methoxyphenyl)methyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(2-phenylethyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
30 2-[4-[hydroxy(furan-2-yl)methyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(2-cyclohexylpropyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(1H-imidazol-4-yl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(phenylmethyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(1H-indol-3-yl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
35 2-[4-(indolin-5-yl)piperidinyl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
6-pyridin-4-yl-2-[2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-yl]pyrimidin-4(1H)-one,
6-pyridin-4-yl-2-[1,2,3,4-tetrahydroisoquinolin-2-yl]pyrimidin-4(1H)-one,
6-pyridin-4-yl-2-[6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl]pyrimidin-4(1H)-

one,

6-pyridin-4-yl-2-[4,5,6,7-tetrahydrothieno[2,3-*c*]pyridin-6-yl]pyrimidin-4(1*H*)-one
and

6-pyridin-4-yl-2-[1,2,3,4-tetrahydrobenzofuro[2,3-*c*]pyridin-2-yl]pyrimidin-4(1*H*)-

5 one, or a salt thereof, or a solvate thereof or a hydrate thereof.

8. A medicament comprising as an active ingredient a substance selected from the group consisting of a pyrimidone derivative according to claim 1.

10 9. A GSK3 β inhibitor selected from the group of a pyrimidone derivative represented by formula (I) or salts thereof, or a solvate thereof or a hydrate thereof according to claim 1.

15 10. Use of a compound according to claim 1 for the preparation of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3 β activity.

11. Use of a compound according to claims 1 to 7 for the preparation of a medicament for preventive and/or therapeutic treatment of a neurodegenerative
20 disease.

12. Use of a compound according to claim 11, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies, vascular dementia; acute stroke,
25 traumatic injuries; cerebrovascular accidents, brain cord trauma, spinal cord trauma; peripheral neuropathies; retinopathies or glaucoma.

13. Use of a compound according to claims 1 to 7 for the preparation of a medicament for preventive and/or therapeutic treatment of non-insulin dependent diabetes; obesity; manic depressive illness; schizophrenia; alopecia; or cancers.
30

14. Use according to claim 13 wherein cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia or virus-induced tumors.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/03639

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C07D401/04	C07D491/04	C07D401/14	C07D495/04	C07D471/04
	A61K31/506	A61P25/28			

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 24782 A (AMGEN) 11 June 1998 (1998-06-11) cited in the application claims -----	1,2,8
P,A	WO 00 18758 A (MITSUBUSHI) 6 April 2000 (2000-04-06) claims; examples 141-4; table 1 -----	1,2,8-14

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

23 August 2001

Date of mailing of the international search report

30/08/2001

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 01/03639

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9824782	A 11-06-1998	AU 5525498 A AU 733877 B AU 6012098 A BG 103512 A BG 103521 A BR 9713850 A BR 9713863 A CN 1246857 A CN 1246858 A CZ 9902015 A CZ 9902016 A EP 0948496 A EP 0948497 A HU 0001140 A HU 0001698 A WO 9824780 A US 6096753 A	29-06-1998 31-05-2001 29-06-1998 31-07-2000 31-07-2000 29-02-2000 14-03-2000 08-03-2000 08-03-2000 17-11-1999 17-11-1999 13-10-1999 13-10-1999 28-04-2001 28-04-2001 11-06-1998 01-08-2000
WO 0018758	A 06-04-2000	AU 5759999 A EP 1115721 A	17-04-2000 18-07-2001